ReviewClinical ophthalmology (Auckland, N.Z.)2014
Advances in gene therapy technologies to treat retinitis pigmentosa.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 75 citations in OpenAlex.
- Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial.Ophthalmology · 2016Trial
- Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind.Ophthalmology · 2015Trial
- 7 Tesla MRI Reveals Brain Structural Abnormalities and Neural Plasticity in RPGR-Related Retinitis Pigmentosa.Journal of clinical medicine · 2025Article
- Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease.Pharmaceutical research · 2024Article
- Retinitis Pigmentosa: From Pathomolecular Mechanisms to Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Genome editing in the treatment of ocular diseases.Experimental & molecular medicine · 2023Review
- CNG channel-related retinitis pigmentosa.Vision research · 2023Article
- Exon Skipping Through Chimeric AntisenseNucleic acid therapeutics · 2022Article
- Argus II retinal prosthesis for retinitis pigmentosa in the Middle East: The 2015 Pan-American Association of Ophthalmology Gradle Lecture.International journal of retina and vitreous · 2021Article
- Polyphenols and Visual Health: Potential Effects on Degenerative Retinal Diseases.Molecules (Basel, Switzerland) · 2021Review
- Effect of Sodium Valproate on the Conformational Stability of the Visual G Protein-Coupled Receptor Rhodopsin.Molecules (Basel, Switzerland) · 2021Article
- RPGR gene therapy presents challenges in cloning the coding sequence.Expert opinion on biological therapy · 2020Review
- Persistent remodeling and neurodegeneration in late-stage retinal degeneration.Progress in retinal and eye research · 2020Review
- Visual Cortical Plasticity in Retinitis Pigmentosa.Investigative ophthalmology & visual science · 2019Article
- Assessment of Postoperative Morphologic Retinal Changes by Optical Coherence Tomography in Recipients of an Electronic Retinal Prosthesis Implant.JAMA ophthalmology · 2019Article
- Learning to see again: biological constraints on cortical plasticity and the implications for sight restoration technologies.Journal of neural engineering · 2017Review
- Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa.Scientific reports · 2017Article
- Peripherin-2 and Rom-1 have opposing effects on rod outer segment targeting of retinitis pigmentosa-linked peripherin-2 mutants.Scientific reports · 2017Article
- Development of the Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ).Translational vision science & technology · 2017Article
- Leber's congenital amaurosis and the role of gene therapy in congenital retinal disorders.International journal of ophthalmology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinitis pigmentosa (RP) is a class of diseases that leads to progressive degeneration of the retina. Experimental approaches to gene therapy for the treatment of inherited retinal dystrophies have advanced in recent years, inclusive of the safe delivery of genes to the human retina. This review is focused on the development of gene therapy for RP using recombinant adenoassociated viral vectors, which show a positive safety record and have so far been successful in several clinical trials for congenital retinal disease. Gene therapy for RP is under development in a variety of animal models, and the results raise expectations of future clinical application. Nonetheless, the translation of such strategies to the bedside requires further understanding of the mutations and mechanisms that cause visual defects, as well as thorough examination of potential adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.